ArticleDrugs - real world outcomes2024
Economic Burden of Parkinson's Disease: A Multinational, Real-World, Cost-of-Illness Study.
Article in Drugs - real world outcomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 7 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Combination therapy of levodopa with safinamide is more effective than with rasagiline and zonisamide in Asian Parkinson's disease patients with motor fluctuations: a systematic review and network meta-analysis of randomized controlled trials.Journal of neurology · 2026Pooled it
- Effects of Telehealth Interventions for People With Parkinson Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials.JMIR mHealth and uHealth · 2026Pooled it
- Detection of parkinson's disease with neuroimaging modalities using machine learning and artificial intelligence: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Glucagon-like peptide-1 receptor agonists and the risk of Parkinson's disease in patients with type 2 diabetes: a systematic review and meta-analysis of large-scale real-world data.Frontiers in endocrinology · 2026Pooled it
- Evaluation of the efficacy and cost-effectiveness of safinamide versus rasagiline: a systematic review.Journal of comparative effectiveness research · 2025Pooled it
- Pooled it
- Direct and indirect costs of idiopathic inflammatory myopathies in adults: A systematic review.PloS one · 2024Pooled it
- Foslevodopa/Foscarbidopa Subcutaneous Infusion Safety and Efficacy in Patients with and Without Prior Deep Brain Stimulation.Advances in therapy · 2026Trial
- Patients' experience with and perspectives on long-term use of continuous subcutaneous infusion of foslevodopa/foscarbidopa in Parkinson's disease.Journal of neurology · 2025Trial
- Brain Health Research in PubMed/MEDLINE: A Bibliometric Analysis of Thematic Structure and Health-Economic Terminology with a Conceptual Performance-Management Framework.Brain sciences · 2026Review
- Pilot Study Employing a Machine Learning Approach as a Potential Method for Predicting Parkinson's Disease Using Voice as a Digital Biomarker and the SHAP Approach for Feature Engineering.Bioengineering (Basel, Switzerland) · 2026Article
- Televisits for Parkinson's disease: benefits and barriers.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Feasibility and acceptability of the cross-national multisectoral OPTIM-PARK intervention for people affected with Parkinson's disease and their family carers.BMC health services research · 2026Article
- National implementation of a digital Parkinson's disease screening programme in Thailand: reach, adoption, and real-world performance of the CheckPD app.BMC public health · 2026Article
- Aerodynamic and Acoustic Characteristics of Nasal Airflow in Parkinson's Disease.Journal of speech, language, and hearing research : JSLHR · 2026Article
- Aryl-Boroxazolidones with Low In Vitro Neurotoxicity and Alleviative Effects on MPTP-Induced Parkinsonism in Mice.Biomolecules · 2026Article
- Article
- Long-term real-world effectiveness of carbidopa/levodopa enteral suspension after 36 months of treatment initiation in advanced Parkinson's disease in the US: final results from the PROviDE study.Clinical parkinsonism & related disorders · 2026Article
- Association Between Relative Fat Mass and Parkinson's Disease in American Adults: A Large Cross-Sectional Study From NHANES.Parkinson's disease · 2026Article
- Searching for a needle in a haystack-ambulatory research in Parkinson's disease in Germany.Frontiers in aging neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease is now one of the fastest-growing neurodegenerative disorders in the developed world, with an increasing prevalence and associated socioeconomic costs. Progression of the disease leads to a gradual deterioration in patients' quality of life, despite optimal treatment, and both medical and societal needs increase, often with the assistance of paid and/or unpaid caregivers.
objectiveWe aimed to quantify the incremental economic burden of Parkinson's disease by disease severity in a real-world setting across differing geographic regions.
methodsDemographics, clinical characteristics, health status, patient quality of life, caregiver burden, and healthcare resource utilization data were drawn from the Adelphi Parkinson's Disease Specific Program™, conducted in the USA, five European countries, and Japan.
resultsA total of 563 neurologists provided data for 5299 individuals with Parkinson's disease; 61% were male, with a mean age of 64 years. Approximately 15% of individuals were deemed to have advanced disease, with significantly more comorbidities, and a poorer quality of life, than those with non-advanced disease. Overall, the mean annual healthcare resource utilization increased significantly with advancing disease, and resulted in a three-fold difference in the USA and Europe. The main drivers behind the high economic burden included hospitalizations, prescription medications, and indirect costs.
conclusionsPeople with Parkinson's disease, and their caregivers, incur a higher economic burden as their disease progresses. Future interventions that can control symptoms or slow disease progression could reduce the burden on people with Parkinson's disease and their caregivers, whilst also substantially impacting societal costs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.